The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials.

IF 12.5 2区 医学 Q1 SURGERY
Yishan Peng, Aijun Liang, Zhi Chen, Bin Yang, Wenke Yu, Jingduo Deng, Yu Fu, Yu Nie, Yuan Cheng
{"title":"The efficacy of adjuvant chemotherapy for curative resected biliary tract cancers: a systematic review and network meta-analysis of randomized clinical trials.","authors":"Yishan Peng, Aijun Liang, Zhi Chen, Bin Yang, Wenke Yu, Jingduo Deng, Yu Fu, Yu Nie, Yuan Cheng","doi":"10.1097/JS9.0000000000002161","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite complete resection, recurrence rate of biliary duct cancer (BTC) remains high, leading to poor prognosis. Postoperative adjuvant chemotherapy (ACT) following radical resection may substantially reduce the recurrence risk by eradicating micrometastatic lesions. However, the benefits of postoperative ACT and the optimal ACT strategy are still unclear for BTC. The objectives of this study are to evaluate the prognostic value of ACT and compare the effectiveness of different ACTs among BTC patients after curative resection.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted across PubMed, Cochrane Library, Web of Science and EMBASE database to identify randomized controlled trials (RCTs) comparing the benefits of ACT versus no intervention or other ACTs in BTC patients after curative resection. A random-effects network meta-analysis was performed to compare overall survival (OS) and relapse-free survival (RFS). The quality of evidence was rated using the GRADE-framework.</p><p><strong>Results: </strong>Eight RCTs comprising 1803 patients were included in the meta-analysis. ACT was associated with significant improvements in 5-year all-cause mortality (4 RCTs, HR 0.93; 95%CI 0.87-1.00, marginally significant; low-certainty evidence), RFS (5 RCTs, HR 0.87; 95%CI 0.78-0.98; moderate-certainty evidence) and OS (7 studies, HR 0.85; 95%CI 0.75-0.96; low-certainty evidence) compared with observation. ACT had significantly better survival benefits on patients with negative margin(R0), lymph node positive (N +) and TNM-stage I/II (P < 0.05). Further network meta-analysis demonstrated fluorouracil-based ACT was significantly inferior to gemcitabine-based ACT (HR 1.20, 95%CI 1.10-1.25) in improving RFS. However, both were superior to observation (P < 0.05). No statistical difference in OS was observed between gemcitabine-based and fluorouracil-based chemotherapy (HR 1.00, 95%CI 0.86-1.20). In subgroup analysis, fluorouracil-based ACT but not gemcitabine-based ACT achieved significantly better OS benefits on patients with N + (HR 0.67; 95%CI 0.52-0.86) and R0 (HR 0.69; 95%CI 0.54-0.88).</p><p><strong>Conclusion: </strong>Compared with observation, ACT should be routinely recommended to improve survival outcomes in BTC patients after curative resection, especially for those with R0, N + and TNM stage I/II. Gemcitabine-based ACT performed better than other chemotherapies on improving RFS. This network meta-analysis provides precise information for determining the best adjuvant treatment for resected BTC. Further thorough and high quality RCTs are needed.</p>","PeriodicalId":14401,"journal":{"name":"International journal of surgery","volume":" ","pages":""},"PeriodicalIF":12.5000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JS9.0000000000002161","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Despite complete resection, recurrence rate of biliary duct cancer (BTC) remains high, leading to poor prognosis. Postoperative adjuvant chemotherapy (ACT) following radical resection may substantially reduce the recurrence risk by eradicating micrometastatic lesions. However, the benefits of postoperative ACT and the optimal ACT strategy are still unclear for BTC. The objectives of this study are to evaluate the prognostic value of ACT and compare the effectiveness of different ACTs among BTC patients after curative resection.

Methods: A comprehensive literature search was conducted across PubMed, Cochrane Library, Web of Science and EMBASE database to identify randomized controlled trials (RCTs) comparing the benefits of ACT versus no intervention or other ACTs in BTC patients after curative resection. A random-effects network meta-analysis was performed to compare overall survival (OS) and relapse-free survival (RFS). The quality of evidence was rated using the GRADE-framework.

Results: Eight RCTs comprising 1803 patients were included in the meta-analysis. ACT was associated with significant improvements in 5-year all-cause mortality (4 RCTs, HR 0.93; 95%CI 0.87-1.00, marginally significant; low-certainty evidence), RFS (5 RCTs, HR 0.87; 95%CI 0.78-0.98; moderate-certainty evidence) and OS (7 studies, HR 0.85; 95%CI 0.75-0.96; low-certainty evidence) compared with observation. ACT had significantly better survival benefits on patients with negative margin(R0), lymph node positive (N +) and TNM-stage I/II (P < 0.05). Further network meta-analysis demonstrated fluorouracil-based ACT was significantly inferior to gemcitabine-based ACT (HR 1.20, 95%CI 1.10-1.25) in improving RFS. However, both were superior to observation (P < 0.05). No statistical difference in OS was observed between gemcitabine-based and fluorouracil-based chemotherapy (HR 1.00, 95%CI 0.86-1.20). In subgroup analysis, fluorouracil-based ACT but not gemcitabine-based ACT achieved significantly better OS benefits on patients with N + (HR 0.67; 95%CI 0.52-0.86) and R0 (HR 0.69; 95%CI 0.54-0.88).

Conclusion: Compared with observation, ACT should be routinely recommended to improve survival outcomes in BTC patients after curative resection, especially for those with R0, N + and TNM stage I/II. Gemcitabine-based ACT performed better than other chemotherapies on improving RFS. This network meta-analysis provides precise information for determining the best adjuvant treatment for resected BTC. Further thorough and high quality RCTs are needed.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
17.70
自引率
3.30%
发文量
0
审稿时长
6-12 weeks
期刊介绍: The International Journal of Surgery (IJS) has a broad scope, encompassing all surgical specialties. Its primary objective is to facilitate the exchange of crucial ideas and lines of thought between and across these specialties.By doing so, the journal aims to counter the growing trend of increasing sub-specialization, which can result in "tunnel-vision" and the isolation of significant surgical advancements within specific specialties.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信